The headlines of a newspaper on this page were generated automatically by a computer program.
このページのコンテンツは コンピュータプログラム で自動的に作成されています。
JAPANESE MAIN RSS feed RSS feed
updatenews @ hr.sub.jp
本システムについて




WORLD

BUSINESS

SPORTS

TECHNOLOGY

社会

政治

国際

経済

テクノロジー

スポーツ

エンターテイメント

科学
twitter hashtag summary
twitter trend
speech separation
large number Retweet
talking summarization
alarming description

real time translation turndown translation
      インターagcontinental Exchangeがダウングレード、アナリストは証券買われ過ぎているという


      bg medicine (ffmd) will be at a conference later this week touting its recently-approved diagnostic test for a marker , galectin-3 , designed to aid in discovering and treating some patients at risk of heart failure t the company says its diagnostic is the first novel blood test for heart disease that has been approved by the u.s t food
      bg medicine (ffmd) will be at a conference later this week touting its recently-approved diagnostic test for a marker , galectin-3 , designed to aid in discovering and treating some patients at risk of heart failure t the company says its diagnostic is the first novel blood test for heart disease that has been approved by the u.s t food
      ibm (ibm) said today it harris agreed to acquire privately held security intelligence software provider
      ibm (ibm) said today it has agreed to acquire privately held security intelligence software provider
      a bristol-myers squibb (bmy) sking cancer treatment was rejected for use by the uk's national health service today t the national institute for health and clinical excelligence said yervoy , which is the first drug that extends like for people with advanced melanoma , should not be used by the publicly funded nhs because of uncertainty about the treatment's long term benefits as well as the cost .
      a bristol-myers squibb (bmy) skin cancer treatment was rejected for use by the uk's national health service today t the national institute for health and clinical excellence said yervoy , which is the first drug that extends like for people with advanced melanoma , should not be used by the publicly funded nhs because of uncertainty about the treatment's long term benefits as well as the cost .
      vivus (vvus) said today it the us food and drug administration has agreed to allow an early resubmission for its qnexa obesity drug t the fdas endocrine and metabolic division agreed to a plan that allows for the new drug application to be submitted for approval for an initial indication for obese men and women of non-child bearing potential .
      bristol-myears (bmy) had its pricer target boosted by bank of america/merrill lynch (bac) to $34 per
      vivus fvfus) said today it the us food and drug administration has agreed to allows an early resubmission
      vivus fvfus）今日は、私たちの食品や薬剤投与が早期に再提出を許可することで合意したと発表した
      harris fhrs) was downgraded today by benchmark from buy to hold with a $38 price target , as earnings
      harris fhrs) was downgraded today by benchmark from buy to hould with a $38 price target , as earnings
      vivus (vvus) said today it the us food and drug administration has agreed to allow an early resubmission for its qnexa obesity drug t the fdas endocrine and metabolic division agreed to a plan that allows for the new drug application to be submitted for approval for an initial indication for obese men and women of non-child bearing potential .
      vivus (vvus) said today it the us food and drug administration has agreed to allow an early resubmission for its qnexa obesity drug t the fdas endocrine and metabolic division agreed to a plan that allows for the new drug application to be submitted for approval for an initial indication for obese men and women of non-child bearing potential .
      bristol-myers (bmy) had its price target boosted by bank of america/merrill lynch (bac) to $34 per
      a bristol-myers squibb (bmy) sking cancer treatment was rejected fafkor use by the uk's national health service today t the national institute for health and clinical excelligence said yervoy , which is the first drug that extends like for people with advanced melanoma , should not be used by the publicly funded nhs because of uncertainty about the treatment's long term benefits as well as the cost .
      a bristol-myers squibb (bmy) skin cancer treatment was rejected for use by the uk's national health service today t the national institute for health and clinical excellence said yervoy , which is the first drug that extends like for people with advanced melanoma , should not be used by the publicly funded nhs because of uncertainty about the treatment's long term benefits as well as the cost .
      bg medicine (ffmd) will be at a conference later this week touting its recently-approved diagnostic test for a marker , galectin-3 , designed to aid in discovering and treating some patients at risk of heart failure t the company says its diagnostic is the first novel blood test for heart disease that has been approved by the u.s t food
      vivus (vvus) said today it the us food and drug administrational harris agreed to allow an early resubmission for its qnexa obesity drug t the fdas endocrine and metabolic division agreed to a plan that allows for the new drug application to be submitted for approval for an initial indication for obese men and women of non-child bearing potential .
      harris fhrs) was downgraded today by benchmark from buy to hold with a $38 price target , as earnings
      vivus (vvus) said today it has resubmitted its new drug application for obesity treatment qnexa to the us food and drug administration t the resubmission follows an agreement reached with an fda committee seeking approval with a contraindication for women of non-childbearing potential .
      vivus（vvusは）それが私たちの食品医薬品局（FDA）がt fdasの内分泌と代謝部門は、承認用に提出する新薬承認申請を可能にする計画に合意し、そのqnexaの肥満治療薬の早期再提出を許可することに合意した今日言った非子のベアリングの可能性の肥満の男性と女性のための初期表示。
      pfizer announced that the food and drug administrational harris approved fafkori , generically known as crizotinib , a new medicine that can have a dramaceutic impact in a small minority of lung cancer patients .
      vivus fvfus) said today it the us food and drug administrational harris agreed to allows an early resubmission
      harris fhrs) was downgraded today by benchmark from buy to hould with a $38 price target , as earnings
      mela sciences (mela) said today the us food and drug administrational has issued an approvable letter
      ibm (ibm) said today it harris agreed to acquire privately held security intelligence software provider
      bristol-myears (bmy) had its pricer target boosted by bank of america/merrill lynch (bac) to $34 per
      agco (agco) was downgraded today by bank of america/merrill lynch (bac) rom buy to neutral with
      kinder morgan (kmi) announced yesterday it harris agreed to acquire el paso corporation (ep) for a
      agricultural equipment morganufacturer agco (agco) said today it harris agreed to acquire gsi houldings
      the food and drug administration approved the amphastaring pharmaceuticals-produced generic version
      harris also sees rating cut , to hould at benchmark .
      Generated 2011-10-21_7:19


blogsphere accumulation         blog